newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

  • AEON Biopharma received a notice on March 31, 2026, from NYSE American indicating non-compliance with Section 1003(a)(ii) of the Company Guide due to a stockholders' deficit of approximately $55 million as of December 31, 2025, & losses in three of its four most recent fiscal years.
  • The new notice requires stockholders' equity of at least $4.0 million & reflects an expected progression from a previous non-compliance notice issued on February 3, 2025, regarding a $2.0 million equity requirement.
  • The Company retains its approved Plan to regain compliance & has until August 3, 2026, to meet listing standards or face potential delisting proceedings.
  • AEON common stock will continue trading on NYSE American under the symbol "AEON" & will carry a ".BC" indicator to denote below-compliance status.
  • The notice does not immediately impact the Company's current listing, business operations, or reporting obligations with the U.S. Securities and Exchange Commission.
  • AEON retains the right to appeal any staff delisting determination in accordance with Section 1010 & Part 12 of the Company Guide.
  • The Company continues to advance ABP-450 as a biosimilar to BOTOX with exclusive rights for therapeutic indications in the U.S., Canada, the EU, the U.K., & other international territories.